Median overall survival of 4 years with upfront CDK4/6 inhibition or in second line ...

The combination of AstraZeneca's Calquence and AbbVie/Roche's Venclexta has become the first all-oral, fixed-duration regimen ...

Treatment approaches have shifted with the introduction of targeted agents, notably Bruton tyrosine kinase (BTK) inhibitors, as well as the emerging role of immunotherapy, according to a new review ...

U.S. Fast Track designation of ART6043 underpinned by promising clinical data to date and high unmet need in gBRCA-mutated ...

As is often the case with cancer treatments, many patients are able to benefit from therapy for a time. Tumor activity ...

Difamilast demonstrated safety, efficacy in multiple eczema trials, joins crisaborole, rof ...

Researchers reviewed the phase 3 findings of a TKI inhibitor treatment compared with aflibercept 2 mg for maintaining vision in patients with wet AMD.

Vascular Endothelial Growth Factor Inhibitor market grows 4.0% CAGR as biosimilars and personalized medicine expand ...

In a study published in February 2026 in JCO Oncology Practice, investigators from Sweden report that influenza vaccination during treatment with immune checkpoint inhibitors was associated with ...

Higher risk for gestational diabetes and some poor newborn outcomes reported, but lower risk for some adverse pregnancy ...

The FDA accepted filing for a new drug application (NDA) today for tirabrutinib for the treatment of adults with relapsed or refractory primary central nervous system lymphoma (R/R PCNSL), according ...